High Expression of MYL9 Indicates Poor Clinical Prognosis of Epithelial Ovarian Cancer
出版年份 2021 全文链接
标题
High Expression of MYL9 Indicates Poor Clinical Prognosis of Epithelial Ovarian Cancer
作者
关键词
-
出版物
Recent Patents on Anti-Cancer Drug Discovery
Volume 16, Issue -, Pages -
出版商
Bentham Science Publishers Ltd.
发表日期
2021-08-16
DOI
10.2174/1574891x16666210706153740
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- miR-6089/MYH9/β-catenin/c-Jun negative feedback loop inhibits ovarian cancer carcinogenesis and progression
- (2020) Longyang Liu et al. BIOMEDICINE & PHARMACOTHERAPY
- Cancer statistics, 2019
- (2019) Rebecca L. Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Expression and clinical significance of Transcription factor 4 (TCF4) in epithelial ovarian cancer
- (2019) Longyang Liu et al. Cancer Biomarkers
- Knockdown of lncRNA HOXD-AS1 suppresses proliferation, migration and invasion and enhances cisplatin sensitivity of glioma cells by sponging miR-204
- (2019) Hui Zhou et al. BIOMEDICINE & PHARMACOTHERAPY
- Epithelial ovarian cancer: Evolution of management in the era of precision medicine
- (2019) Stephanie Lheureux et al. CA-A CANCER JOURNAL FOR CLINICIANS
- MYH9 overexpression correlates with clinicopathological parameters and poor prognosis of epithelial ovarian cancer
- (2019) Longyang Liu et al. Oncology Letters
- Expression pattern and prognostic significance of myosin light chain 9 (MYL9): a novel biomarker in glioblastoma
- (2019) Banavathy S Kruthika et al. JOURNAL OF CLINICAL PATHOLOGY
- Comprehensive analysis of expression profiles of long non‑coding RNAs with associated ceRNA�network involved in gastric cancer progression
- (2019) Wei Gu et al. Molecular Medicine Reports
- Human epididymis protein 4 antigen‐autoantibody complexes complement cancer antigen 125 for detecting early‐stage ovarian cancer
- (2019) Wei‐Lei Yang et al. CANCER
- Inhibition of PI3K/AKT/mTOR and MAPK signaling pathways decreases progranulin expression in ovarian clear cell carcinoma (OCCC) cell line: a potential biomarker for therapy response to signaling pathway inhibitors
- (2019) Carlos Eduardo Perez-Juarez et al. MEDICAL ONCOLOGY
- Identification of key biomarkers associated with development and prognosis in patients with ovarian carcinoma: evidence from bioinformatic analysis
- (2019) Jiayu Shen et al. Journal of Ovarian Research
- Low expression of KIF7 indicates poor prognosis in epithelial ovarian cancer
- (2019) Yaoshan Yao et al. Cancer Biomarkers
- Cancer screening in the United States, 2018: A review of current American Cancer Society guidelines and current issues in cancer screening
- (2018) Robert A. Smith et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Ovarian cancer statistics, 2018
- (2018) Lindsey A. Torre et al. CA-A CANCER JOURNAL FOR CLINICIANS
- PARP Inhibitors in Ovarian Cancer
- (2018) Gloria Mittica et al. Recent Patents on Anti-Cancer Drug Discovery
- Inflammation is a key contributor to ovarian cancer cell seeding
- (2018) Dongyu Jia et al. Scientific Reports
- Expression and prognostic significance of MYL9 in esophageal squamous cell carcinoma
- (2017) Jian-Hua Wang et al. PLoS One
- Cancer statistics in China, 2015
- (2016) Wanqing Chen et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Non-muscle myosins in tumor progression, cancer cell invasion, and metastasis
- (2014) Jessica L. Ouderkirk et al. Cytoskeleton
- MYLK and MYL9 expression in non-small cell lung cancer identified by bioinformatics analysis of public expression data
- (2014) Xiang Tan et al. TUMOR BIOLOGY
- Decreased expression of myosin light chain MYL9 in stroma predicts malignant progression and poor biochemical recurrence-free survival in prostate cancer
- (2013) Ya-qiang Huang et al. MEDICAL ONCOLOGY
- Identification of candidate colon cancer biomarkers by applying a random forest approach on microarray data
- (2012) ZHI YAN et al. ONCOLOGY REPORTS
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started